



ASX Release

PROPOSED SHARE CONSOLIDATION

Sydney, Tuesday 3 July 2018

The board of Memphasys Limited (ASX: MEM) has resolved, subject to shareholder approval, to undertake a consolidation of the Company's issued capital on a 15:1 basis (**Consolidation**).

The purpose of Consolidation is to decrease the number of shares on issue to a more manageable quantity and to enable smoother, less volatile share trading.

A resolution to this effect will be put to shareholders at a general meeting of the Company to be held on 6 August 2018 (**General Meeting**). The notice of General Meeting will be dispatched to shareholders and announced to ASX on Friday, 6 July 2018 (**Notice of Meeting**).

If shareholders approve the Consolidation at the General Meeting, the issued share capital of the Company will reduce from 5,108,829,192 ordinary shares to approximately 340,588,613 ordinary shares (assuming no options are exercised prior to the Consolidation and no further shares are issued). The number of options on issue will reduce from 224,971,876 to approximately 14,998,125, while the exercise price of the options will increase by a factor of 15.

As the Consolidation applies equally to all the Company's security holders, individual holdings will be reduced in the same ratio. The value of individual holdings at the time of the Consolidation will not change (subject only to the rounding of fractions).

The timetable for the Consolidation (assuming approval by shareholders) is as follows:

Action	Date
<i>Company sends out Notice of Meeting seeking Shareholder approval for the Consolidation.</i>	6 July 2018
<i>Company tells ASX that Shareholders have approved the Consolidation</i>	6 August 2018
<i>Last day for trading in pre-Consolidation Securities</i>	7 August 2018
<i>Trading in post-Consolidation starts on a deferred settlement basis</i>	8 August 2018
<i>Last day for Company to register transfers on a pre-Consolidation basis</i>	9 August 2018
<i>First day for Company to send to each holder notice of the change in their details of holdings.</i>	10 August 2018

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

<i>First day for the Company to register Securities on a post-Consolidation basis and first day for issue of holding statements</i>	
<i>Change of details of holdings date. Deferred settlement market ends</i>	16 August 2018
<i>Last day for Securities to be entered into holders' Security holdings</i>	
<i>Last day for the Company to send to each holder notice of the change in their details of holding</i>	

Upon release of the Notice of Meeting, Shareholders are encouraged to review the Explanatory Memorandum in the Notice of Meeting or contact the Company for further details.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.